
Tarsus Pharmaceuticals Revenue | TARS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Tarsus Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 451 M | 183 M | 17.4 M | 25.8 M | 57 M | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 451 M | 17.4 M | 147 M |
Quarterly Revenue Tarsus Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 195 M | 174 M | 162 M | 152 M | 119 M | 103 M | 78.3 M | 66.4 M | 48.1 M | 40.8 M | 27.6 M | 13.1 M | 1.87 M | - | 2.5 M | 10 M | - | 15.3 M | 539 K | 338 K | 1.24 M | 22 M | 33.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 195 M | 338 K | 60.2 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Sutro Biopharma
STRO
|
102 M | $ 8.6 | -1.38 % | $ 73.1 M | ||
|
Supernus Pharmaceuticals
SUPN
|
719 M | $ 36.28 | 1.88 % | $ 2.05 B | ||
|
TG Therapeutics
TGTX
|
616 M | $ 63.39 | -2.3 % | $ 9.15 B | ||
|
Aphria Inc.
APHA
|
543 M | - | -0.45 % | $ 4.87 B | ||
|
Viridian Therapeutics
VRDN
|
70.8 M | $ 29.91 | -4.87 % | $ 3.05 B | ||
|
Aerpio Pharmaceuticals, Inc.
ARPO
|
15 M | - | -0.90 % | $ 104 M | ||
|
Chiasma, Inc.
CHMA
|
1.11 M | - | -6.00 % | $ 238 M | ||
|
vTv Therapeutics
VTVT
|
1.02 M | $ 16.0 | -2.2 % | $ 64.2 M | ||
|
Adamas Pharmaceuticals, Inc.
ADMS
|
74.5 M | - | - | $ 376 M | ||
|
Xenon Pharmaceuticals
XENE
|
7.5 M | $ 36.89 | -1.78 % | $ 2.92 B | ||
|
Xeris Pharmaceuticals
XERS
|
292 M | $ 16.95 | 2.02 % | $ 2.72 B | ||
|
X4 Pharmaceuticals
XFOR
|
6.5 M | $ 3.01 | 1.69 % | $ 127 M | ||
|
Cerecor Inc.
CERC
|
6.7 M | - | -1.68 % | $ 283 M | ||
|
Auris Medical Holding Ltd.
EARS
|
174 K | - | -1.77 % | $ 39.2 M | ||
|
Dicerna Pharmaceuticals, Inc.
DRNA
|
164 M | - | 0.34 % | $ 2.98 B | ||
|
ERYTECH Pharma S.A.
ERYP
|
1.8 M | - | 1.3 % | $ 27.7 M | ||
|
GW Pharmaceuticals plc
GWPH
|
527 M | - | - | $ 6.81 B | ||
|
22nd Century Group
XXII
|
17.6 M | $ 0.32 | -19.83 % | $ 58.9 K | ||
|
Kadmon Holdings, Inc.
KDMN
|
8.29 M | - | - | $ 1.7 B | ||
|
Liminal BioSciences
LMNL
|
401 K | - | - | $ 256 M | ||
|
argenx SE
ARGX
|
36.4 M | $ 926.42 | -1.66 % | $ 56.8 B | ||
|
Tonix Pharmaceuticals Holding Corp.
TNXP
|
13.1 M | $ 2.33 | -7.25 % | $ 19.8 M | ||
|
Zai Lab Limited
ZLAB
|
460 M | $ 21.01 | -4.16 % | $ 23 B | ||
|
Neos Therapeutics, Inc.
NEOS
|
64.6 M | - | -2.54 % | $ 57.2 M | ||
|
Zentalis Pharmaceuticals
ZNTL
|
67.4 M | $ 1.37 | 0.74 % | $ 98.5 M | ||
|
Zoetis
ZTS
|
9.47 B | $ 78.81 | -2.47 % | $ 34.9 B | ||
|
Osmotica Pharmaceuticals plc
OSMT
|
178 M | - | -10.74 % | $ 89.9 M | ||
|
Pandion Therapeutics, Inc.
PAND
|
8.78 M | - | - | $ 1.77 B | ||
|
Xenetic Biosciences
XBIO
|
2.98 M | $ 1.47 | -4.55 % | $ 2.5 M | ||
|
Translate Bio, Inc.
TBIO
|
139 M | - | - | $ 2.81 B | ||
|
Trillium Therapeutics Inc.
TRIL
|
148 K | - | - | $ 1.94 B | ||
|
Acceleron Pharma Inc.
XLRN
|
74 M | - | - | $ 10.9 B | ||
|
Zogenix, Inc.
ZGNX
|
13.6 M | - | -4.97 % | $ 664 M | ||
|
ZIOPHARM Oncology, Inc.
ZIOP
|
146 K | - | -7.58 % | $ 264 M | ||
|
Taysha Gene Therapies
TSHA
|
9.77 M | $ 3.71 | -1.72 % | $ 1.19 B | ||
|
Vericel Corporation
VCEL
|
276 M | $ 57.41 | -1.46 % | $ 2.89 B | ||
|
Vir Biotechnology
VIR
|
68.6 M | $ 8.37 | -5.64 % | $ 1.16 B | ||
|
Veracyte
VCYT
|
517 M | $ 25.08 | 0.16 % | $ 1.97 B | ||
|
Viking Therapeutics
VKTX
|
10.7 K | $ 24.72 | -4.35 % | $ 2.79 B | ||
|
Vanda Pharmaceuticals
VNDA
|
216 M | $ 3.44 | -6.27 % | $ 203 M | ||
|
VistaGen Therapeutics
VTGN
|
1.27 M | $ 0.16 | -12.33 % | $ 6.09 M |